Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Direxion Daily TSLA Bull 2X Shares trades at $12.11. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| ACAD | TSLL | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $23.03 |
52-Week Low | $20.06 | $10.09 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TSLL trades at $13.95, up 13.41% in the last 24 hours, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Support levels are established at $13 and $12, with resistance near $15. Recent news highlights continued investor interest in leveraged ETF strategies tied to high-growth sectors like Tesla.
The outlook for TSLL is cautiously optimistic, driven by strong technical momentum and sector interest, but risks include market volatility and dependency on underlying asset performance. Investors should weigh the potential for amplified returns against the inherent leverage risks in the ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
